InsidersTradesSigma
Track the Therapeutic Solutions International, INC. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Therapeutic Solutions International, INC. has logged 34 public disclosures. Market capitalisation: €512k. The latest transaction was filed on 2 October 2024 (Attribution). Among the most active insiders: DIXON TIMOTHY G. All data is accessible without an account.
34
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
38Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 October 2024
Declarations34 total
10,000,000 shares@ US$0.00092.0% of flowCommon StockSEC:0001493152-24-039151:0
55,555,555 shares@ US$0.00094.8% of flowCommon StockSEC:0001493152-24-039152:0
13,333,333 shares@ US$0.00060.8% of flowCommon StockSEC:0001493152-24-027797:0
20,000,000 shares@ US$0.00061.2% of flowCommon StockSEC:0001493152-24-027079:0
10,000,000 shares@ US$0.00061.3% of flowCommon StockSEC:0001493152-24-027081:0
25,000,000 shares@ US$0.00082.0% of flowCommon StockSEC:0001493152-24-026652:0
10,000,000 shares@ US$0.00081.8% of flowCommon StockSEC:0001493152-24-026656:0
37,500,000 shares@ US$0.00082.9% of flowCommon StockSEC:0001493152-24-022090:0
10,000,000 shares@ US$0.00081.8% of flowCommon StockSEC:0001493152-24-022093:0
42,857,142 shares@ US$0.00073.0% of flowCommon StockSEC:0001493152-24-015329:0
15,000,000 shares@ US$0.00072.4% of flowCommon StockSEC:0001493152-24-015326:0
10,000,000 shares@ US$0.00090.9% of flowCommon StockSEC:0001493152-24-007808:0
10,000,000 shares@ US$0.00092.0% of flowCommon StockSEC:0001493152-24-007810:0
20,000,000 shares@ US$0.00156.9% of flowCommon StockSEC:0001493152-23-037416:0
70,000,000 shares@ US$0.001510.5% of flowCommon StockSEC:0001493152-23-037414:0
4,000,000 shares@ US$0.00494.5% of flowCommon StockSEC:0001493152-23-000989:0
4,081,632 shares@ US$0.00492.0% of flowCommon StockSEC:0001493152-23-000987:0
4,000,000 shares@ US$0.0065.5% of flowCommon StockSEC:0001493152-22-037188:0
4,000,000 shares@ US$0.0062.4% of flowCommon StockSEC:0001493152-22-037187:0
3,000,000 shares@ US$0.00997.3% of flowCommon StockSEC:0001493152-22-030365:0
3,777,777 shares@ US$0.00994.0% of flowCommon StockSEC:0001493152-22-030360:0
1,500,000 shares@ US$0.0111.7% of flowCommon StockSEC:0001493152-22-025506:0
1,500,000 shares@ US$0.01161.8% of flowCommon StockSEC:0001493152-22-025388:0
2,400,000 shares@ US$0.02511.48% mcap9.5% of flowCommon StockSEC:0001493152-22-009629:0
2,000,000 shares@ US$0.02511.23% mcap7.8% of flowCommon StockSEC:0001493152-22-009253:0
25 of 34 declarations
关于 Therapeutic Solutions International, INC.
Therapeutic Solutions International, Inc.（股票代码：TSOI）是一家总部位于美国的微市值医疗保健公司，目前与美国场外交易市场相关联，而非纽约证券交易所/纳斯达克。该公司总部位于美国，美国证券交易委员会（SEC）备案文件显示其公司已迁至爱达荷州埃尔克城。在业务方面，TSOI 将自己定位为一家生物技术和医疗解决方案开发商，专注于免疫调节、细胞疗法以及与肿瘤学和炎症性疾病相关的项目。其 SEC 披露文件表明其运营规模非常小，严重依赖外部融资，并存在早期生物制药公司常见的持续经营和稀释风险。 从业务线角度来看，该公司历来围绕几个开发主题进行沟通：基于干细胞的治疗候选药物、免疫系统调节以及严重疾病环境中的临床或临床前应用。最常被引用的资产之一是 JadiCell™，该公司将其描述为旗舰细胞治疗项目，此外还有与癌症和其他高度未满足需求适应症相关的其他举措。TSOI 的竞争地位仍高度不确定，取决于临床验证、监管进展以及其长期为研发提供资金的能力。在这方面，它无法与拥有多元化商业特许经营权的大型制药公司相提并论；相反，其股权故事主要由里程碑事件和二元结果驱动。 从地理上看，该公司似乎主要以美国为中心。SEC 备案文件表明其运营足迹集中在爱达荷州，早期公司文件中曾提及加利福尼亚州。没有明确证据表明其拥有可与全球制药商相媲美的广泛国际商业平台。任何更广泛的地理覆盖范围都可能通过潜在的合作伙伴关系、许可或未来的开发关系实现，而非通过已建立的跨国销售网络。 SEC 备案文件中近期亮点包括在 Form 4 上报告的内部人交易，此类交易在此类股票中通常会引起密切关注。该公司的监管文件还强调了持续的流动性压力、对未来融资的依赖以及在推进其开发管线的同时维持运营的需求。因此，对于法语投资者而言，TSOI 应被视为一家高度投机的美国生物技术微市值公司，其价值更多地锚定在临床和融资催化剂上，而非传统的基于盈利的估值指标。
